123 related articles for article (PubMed ID: 28967548)
1. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
[TBL] [Abstract][Full Text] [Related]
2. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
Shih YC; Mauskopf J; Borker R
Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of asthma therapy: a comprehensive review.
Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
[TBL] [Abstract][Full Text] [Related]
6. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?
Dilokthornsakul P; Chaiyakunapruk N; Campbell JD
J Asthma; 2017 Jan; 54(1):17-23. PubMed ID: 27284904
[TBL] [Abstract][Full Text] [Related]
7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
8. [Medication adherence in asthma therapy--a structured review].
Fischer J; Wimmer A; Mahlich J
Pneumologie; 2013 Jul; 67(7):406-14. PubMed ID: 23797492
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
[TBL] [Abstract][Full Text] [Related]
11. Health economics of asthma: assessing the value of asthma interventions.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2008 Dec; 63(12):1581-92. PubMed ID: 19032230
[TBL] [Abstract][Full Text] [Related]
12. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
Faria R; McKenna C; Palmer S
Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
[TBL] [Abstract][Full Text] [Related]
14. A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients.
Manfrin A; Tinelli M; Thomas T; Krska J
BMC Health Serv Res; 2017 Apr; 17(1):300. PubMed ID: 28438152
[TBL] [Abstract][Full Text] [Related]
15. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of risk factors and health outcomes among persons with asthma.
Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
[TBL] [Abstract][Full Text] [Related]
19. Asthma outcomes: healthcare utilization and costs.
Akinbami LJ; Sullivan SD; Campbell JD; Grundmeier RW; Hartert TV; Lee TA; Smith RA
J Allergy Clin Immunol; 2012 Mar; 129(3 Suppl):S49-64. PubMed ID: 22386509
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
